![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Bristol-Myers Company plans to file with the Food and Drug Administration for approval of carboplatin, a cisplatin derivative. The drug is already on the market in Canada, England, Switzerland, Belgium, Sweden, Ireland, Australia, New Zealand, and Hong Kong. Approved indications, which vary by country, are for ovarian cancer (as a first- and/or second-line agent), small cell lung cancer, and head and neck cancer. The application to the FDA will seek approval of carboplatin as both a first- and second-line chemotherapeutic agent in the treatment of ovarian cancer.